Dharminder Chahal

Dharminder has an extensive network in the life science industry and holds a strong track record in direct involvement of complex corporate transactions. These include the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, deVGen to Syngenta and Octoplus to Dr. Reddy’s. Indirectly, with Van Herk Investments as important shareholder, he was involved in the recent sale of Ablynx to Sanofi and the deal between Galapagos and Gillead. Furthermore, he is CEO and founder of SkylineDx, fund manager at Swanbridge Capital and active for several companies as board member or advisor.